These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 2546504)

  • 21. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
    Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
    Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined chemotherapy and differentiation therapy in the treatment of advanced non-small-cell lung cancer.
    Recchia F; Sica G; De Filippis S; Rea S; Frati L
    Anticancer Res; 1997; 17(5B):3761-5. PubMed ID: 9427776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Phase II study of a three-drug combination of ifosfamide, cisplatin and vindesine in non-small-cell lung cancer].
    Ohnoshi T; Hiraki S; Ueoka H; Tamura T; Kawahara S; Yonei T; Yamashita H; Ishii J; Tamai M; Egawa T
    Gan To Kagaku Ryoho; 1988 Jan; 15(1):115-9. PubMed ID: 2827585
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative study on vindesine plus cisplatin treatment of advanced non-small cell lung cancer--three divided doses (35 mg/m2, day 1, 8, 15) and single dose (80 mg/m2, day 1) of cisplatin. Chiba Lung Cancer Study Group].
    Nagao K; Fujisawa T; Miyamoto T; Kikuchi N; Takizawa H; Satoh K; Yamagishi F; Yamaguchi T; Mizutani F; Nakano K
    Gan To Kagaku Ryoho; 1991 Mar; 18(3):425-30. PubMed ID: 1848421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Prospective randomized study of HMVP, MVP, and HVP regimens in treatment of advanced non-small cell lung cancer].
    Gao JF; Li CS; Zhang BC; Du GZ; Zhang XH; Wang J; Zhu YZ; Ou WL; Yang B
    Ai Zheng; 2004 Apr; 23(4):435-8. PubMed ID: 15087034
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Lung toxicity of trimodality chemoradiotherapy with mitomycin C, vindesine, and cisplatin followed by surgery for locally advanced non-small cell lung cancer].
    Sawa T; Yoshida T; Ishiguro T; Ogawara M; Kawahara M; Yamamoto S; Yokota S; Maeda H; Asamoto H
    Gan To Kagaku Ryoho; 2003 Oct; 30(11):1745-9. PubMed ID: 14619509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [An early phase II trial combining cisplatin, carboplatin and vindesine in patients with inoperable non-small cell lung cancer].
    Haneda H; Koizumi M; Hayashi T
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):227-31. PubMed ID: 10700892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro.
    Oshita F; Yamamoto N; Fukuda M; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
    Cancer Res; 1995 Jun; 55(11):2334-7. PubMed ID: 7757984
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative study of three different chemotherapy protocols for advanced non-small-cell lung cancer].
    Chen L; Wang J; Chu X
    Zhonghua Zhong Liu Za Zhi; 1999 Mar; 21(2):151-2. PubMed ID: 11776862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Comparative study on quality of life between weekly and monthly chemotherapy with cisplatin, vindesine and mitomycin C in patients with non-small cell lung cancer].
    Ishihara Y; Ichiwata T; Kuramitsu K; Yoneda S; Yamamoto M; Takizawa T; Ogata T; Uchiyama T; Yoshida K
    Gan To Kagaku Ryoho; 1998 Jun; 25(7):1013-20. PubMed ID: 9644316
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Dose intensity chemotherapy in lung cancer].
    Takada M; Fukuoka M; Negoro S; Masuda N; Kudo S
    Gan To Kagaku Ryoho; 1990 Oct; 17(10):2005-12. PubMed ID: 1699498
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Current results of chemotherapy in non-small cell lung cancer].
    Fukuoka M; Negoro S; Takada M; Matsui K; Takifuji N; Masuda N; Kawahara M; Furuse K
    Nihon Kyobu Shikkan Gakkai Zasshi; 1990 Feb; 28(2):203-9. PubMed ID: 2162439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Benefits of cisplatin-based polychemotherapy in non-small cell bronchogenic carcinoma. Kyushu Lung Cancer Chemotherapy Study Group].
    Ohta M; Hara N; Ichikawa Y; Kanda T; Shima K; Tamura K; Hokama M
    Gan To Kagaku Ryoho; 1988 Jun; 15(6):1901-8. PubMed ID: 2454615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Concurrent high-dose thoracic irradiation plus daily low-dose cisplatin and vindesine in locally advanced unresectable stage III non-small cell lung cancer].
    Nakano K; Kumagai K; Ishida H; Kohjima N; Hiramoto T; Hada Y
    Gan To Kagaku Ryoho; 1996 Jan; 23(1):57-61. PubMed ID: 8546470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Induction chemotherapy with mitomycin, vindesine, and cisplatin for stage IIIA (T1-3, N2) unresectable non-small-cell lung cancer: final results of the Toronto phase II trial.
    Burkes RL; Shepherd FA; Blackstein ME; Goldberg ME; Waters PF; Patterson GA; Todd T; Pearson FG; Jones D; Farooq S; McGlaughlin J; Ginsberg RJ
    Lung Cancer; 2005 Jan; 47(1):103-9. PubMed ID: 15603860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Clinical study of combination chemotherapy with cisplatin, ifosfamide, 5-FU (CIF therapy) of inoperable adenocarcinoma and large cell carcinoma of the lung].
    Fujita A; Sasaki H; Mori T; Nakajima S; Sekine K; Inoue Y; Honda R; Asakawa M; Suzuki A
    Gan To Kagaku Ryoho; 1991 Jan; 18(1):51-5. PubMed ID: 1846283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The relation between myelotoxicity and performance status or aging in chemotherapy of non-small cell lung cancer].
    Oshita F; Shinkai T; Miya T; Kojima A; Ohe Y; Tamura T; Sasaki Y; Eguchi K; Saijo N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1991 Feb; 29(2):231-8. PubMed ID: 1851904
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized trial in inoperable non-small-cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin.
    Fukuoka M; Masuda N; Furuse K; Negoro S; Takada M; Matsui K; Takifuji N; Kudoh S; Kawahara M; Ogawara M
    J Clin Oncol; 1991 Apr; 9(4):606-13. PubMed ID: 1648597
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized study of two vindesine plus cisplatin-containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer.
    Rosell R; Abad-Esteve A; Moreno I; Barnadas A; Carles J; Fernandez C; Ribelles N; Culubret M
    Cancer; 1990 Apr; 65(8):1692-9. PubMed ID: 2156597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Polychemotherapy of non-small cell bronchial cancer with mitomycin C, ifosfamide and vindesine].
    Laumen R; Jungbluth H; von Pawel J; Häussinger K; Otto M; Krieger H
    Pneumologie; 1990 Feb; 44 Suppl 1():590. PubMed ID: 2164206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.